New Provider updates -Pharmacy Clinical Edits have been posted

Pharmacy Clinical Edits and Preferred Drug list

September 29, 2023 Pharmacy Updates and Edits MO HealthNet is required to complete an annual review of all drug coverage criteria per 13 CSR 70-20.200 Drug Prior Authorization Process. Web page:https://dss.mo.gov/mhd/cs/pharmacy/pages/clinedit.htm  Annual Renewal Effective: 10/05/2023 Alpha-Glucosidase Inhibitors Amylin Analogs PDL Atopic Dermatitis Agents, Immunomodulators PDL Edit Biguanides & Combination Agents PDL Biosimilar vs Reference Products Fiscal Edit Colony Stimulating Factors PDL Cryopyrin-Associated Periodic Syndrome (CAPS) Agents PDL Dose Optimization Fiscal Edit DPP-IV Inhibitors PDL Erythropoiesis Stimulating Agents PDL Glucagon Agents PDL Growth Hormones & Growth Hormone Releasing Factors, Select Agents PDL Growth Hormones Somatropin Agents PD Insulins Long Acting PDL Insulins Mix PDL Insulins-Non-Analog PDL Insulins Rapid Acting PDL Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Non-Oral PDL Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Oral PDL Meglitinide Agents PDL Methotrexate Agents PDL Multiple Sclerosis, Injectable Agents PDL Multiple Sclerosis, Oral Agents PDL Prior Authorization Required Fiscal Edit Psoriasis Agents - Oral PDL Psoriasis Agents – Topical PDL Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & Combination Agents PDL Sulfonylurea Agents, Second Generation PDL Targeted Immune Modulators, IL-17A Antibody/IL-17 Receptor Antagonists PDL Targeted Immune Modulators, IL-23 Inhibitors & IL-23/IL-12 Inhibitors PDL Targeted Immune Modulators, Interleukin-6 (IL-6) Receptor Inhibitors PDL Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors PDL Targeted Immune Modulators, Misc. Allergy and Asthma Related Monoclonal Antibodies PDL (formerly Respiratory Monoclonal Antibody PDL) Targeted Immune Modulators, Select Agents PDL Targeted Immune Modulators, Tumor Necrosis Factor (TNF) Inhibitors PDL Thiazolidinediones & Combination Agents PDL Thromobocytopenia Agents PDL Urinary Tract Antispasmodics PDL   New Edit Effective: 10/05/2023 Bleeding Disorder Agents PDL   Annual Renewal Effective: 10/06/2023 Fluoroquinolones – Otic PDL   Contact Us For questions about pharmacy or MORx, please email: MHD.PharmacyAdmin@dss.mo.gov. For questions about psychology, exceptions, or medical pre-certifications, please email: Clinical.Services@dss.mo.gov For all other questions or comments, please email: Ask.MHD@dss.mo.gov Our Mission: Empower Missourians to live safe, healthy, and productive lives.     Note: replies to this email address will not be monitored.

---

This newsletter is provided to you by the Missouri Department of Social Services

---

This email was sent to ignoble.experiment@arconati.us using GovDelivery Communications Cloud on behalf of: Missouri Department of Social Services · Broadway State Office Building PO Box 1527 · Jefferson City, MO 65102